Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with non-small cell lung cancer (a type of lung cancer) through a tissue or cell sample, where the cancer is at a certain stage (stage IIB or III), has spread to nearby lymph nodes, cannot be removed with surgery, and where the protein PD-L1 has been tested for.
• People whose cancer includes both a main tumour and at least one affected lymph node in the chest or neck area.
• People who have received up to 4 rounds of treatment (such as chemotherapy) for this cancer before joining, or who have had chemotherapy for a different cancer in the past.
• People who have chosen not to have surgery, as well as those whose cancer cannot be surgically removed for medical or technical reasons.
• People who have separate tumour nodules within the same section (lobe) of the lung where the main tumour is located.
• People whose doctors consider them suitable for treatment aimed at curing the cancer using a combination of approaches.
• People who have had recent brain imaging (MRI preferred, or CT scan) and chest CT scan before joining the trial.
• People who have had a PET/CT scan within 60 days before joining that shows no sign the cancer has spread to distant parts of the body.
• People whose main tumour measures 7 cm or smaller.
• People aged 18 or older.
• People who are reasonably active and able to care for themselves, based on a standard medical scale (ECOG performance status 0–2).
• People whose blood counts (such as platelets, white blood cells, and haemoglobin) are considered adequate by their treating doctor to undergo chemotherapy and radiation at the same time.
• People whose kidneys are functioning well enough, based on a calculation of kidney clearance rate (at least 25 mL/min).
• People who have a small amount of fluid around the lung that has been confirmed not to be caused by cancer — or where the fluid is too small to safely sample and is not visible on a chest X-ray.
• People whose medical history suggests their doctor considers them suitable for follow-up immunotherapy treatment after the main treatment phase.
• People who have or have had another cancer that is not expected to interfere with this trial's treatment or results.
• People who test negative for pregnancy within 14 days before joining (where applicable).
• People who are willing to provide informed consent before entering the study, and in the United States, permission to share their health information.

Who may not be able to join:

• People who have previously had radiation therapy to the same area where this cancer is located, or to a nearby area where the radiation fields would overlap in a way the treating doctor determines would interfere with treatment.
• People whose cancer does not include both an identifiable main tumour and at least one affected lymph node — for example, those with a tumour but no involved lymph nodes, or lymph node involvement but no identifiable primary tumour.
• People whose main tumour is located very close to the central airways and near the affected lymph nodes in a way that would cause significant overlap of the radiation treatment areas (confirm with trial site for specific technical details).
• People who are currently pregnant or who are unwilling to stop breastfeeding.
• People who could become pregnant or could cause a partner to become pregnant, who are unwilling to use highly effective contraception during treatment and for the required period after the last dose of treatment, because the treatments used in this trial may cause serious harm to an unborn child.

Important: Always verify eligibility with the trial site directly before applying.